Skip to main content
Clinical Trials/NCT03104179
NCT03104179UnknownNot Applicable

Removal of Cytokines in Patients Undergoing Cardiac Surgery With CPB (The REMOTE Study)

Klinikum Nürnberg1 site in 1 country80 target enrollmentStarted: May 1, 2017Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Enrollment
80
Locations
1
Primary Endpoint
Cytokine levels following CPB

Study Overview

Brief Summary

In a lot of cases during cardiac surgery cardiopulmonary bypass initiates SIRS due to release of cytokines during immunological response.

They are induced by different types of inductors ( intrinsic and extrinsic). High levels of inflammation markers like TNF-a, IL 6 and IL 10 as well as TGF-ß are detectable after 2 hours of surgery.

Beside the inflammation acute phase parameters like fibrinogen, ferritin are increased. These changes lead to rheology impairments.

These strong reactions lead to dysfunction of different organs possibly culminating in a multi organ failure.

There is a correlation between amounts of cytokines and mortality. Often AKI occurs after CPB with a rate of about 30%. Dysfunctions of organ function are often connected with increased mortality, prolonged mechanical ventilation , septic complications, increased catecholamine dosages and prolonged length of ICU stay.

Use of cytokine adsorption within the extracorporeal circuit during CBP can affect the circulating cytokine levels during and after CPB and lead to a diminished inflammatory response, acute phase reaction as well as reduction of organ failure.

Detailed Description

In a lot of cases during cardiac surgery cardiopulmonary bypass initiates SIRS due to release of cytokines during immunological response.

They are induced by different types of inductors ( intrinsic and extrinsic). High levels of inflammation markers like TNF-a, IL 6 and IL 10 as well as TGF-ß are detectable after 2 hours of surgery.

Beside the inflammation acute phase parameters like fibrinogen, ferritin are increased. These changes lead to rheology impairments.

These strong reactions lead to dysfunction of different organs possibly culminating in a multi organ failure.

There is a correlation between amounts of cytokines and mortality. Often AKI occurs after CPB with a rate of about 30%. Dysfunctions of organ function are often connected with increased mortality, prolonged mechanical ventilation , septic complications, increased catecholamine dosages and prolonged length of ICU stay.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
65 Years to 85 Years (Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Elective cardiac surgery with CPB
  • Signed informed consent
  • CPB time > 75 min.
  • Comorbidities:
  • diabetes mellitus
  • CHF, NYHA class 1 and 2
  • liver dysfunction (1, 2)
  • kidney dysfunction (1, 2)
  • hypertension
  • arteriosclerosis

Exclusion Criteria

  • Age < 65 years
  • Declined informed consent
  • Planed temperature < 32 C
  • Emergency surgery
  • Preexisting renal replacement therapy
  • Preexisting kidney transplantation
  • Administration of immunosuppressants like steroids
  • AIDS with CD 4 < 200/
  • Participation in other trials

Arms & Interventions

Treatment

Experimental

CPB with Cytosorb

Intervention: Cytosorb Adsorber (Device)

Control

No Intervention

CPB without Cytosorb (Control)

Outcomes

Primary Outcomes

Cytokine levels following CPB

Time Frame: 72 hours

Evaluation of cytokine adsorber effect on cytokine levels intra- and post

Secondary Outcomes

  • Level of haptoglobin(72 hours)
  • Intra- and postoperative catecholamine dosages(until ICU discharge, expected average 4 days)
  • Level of transferrin(72 hours)
  • postoperative renal failure necessitating RRT(until ICU discharge, expected average 4 days)
  • Level of ferritin(72 hours)
  • Length of ICU stay(until discharge from ICU, expected average 4 days)
  • Length of hospital stay(up to hospital discharge, expected average 14 days)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

PD Dr. med. Giuseppe Santarpino

PD, Dr. med

Klinikum Nürnberg

Study Sites (1)

Loading locations...

Similar Trials